Russian pharma-sector asset structures face new court-driven constraints post-2022. What changed and what owners should do now. Make an enquiry.
Following the structural disruptions that reshaped the regulatory treatment of foreign-held Russian assets from 2022 onwards, family offices and private wealth advisers with pharmaceutical-sector positions in Russia face a materially altered landscape as of early 2027. Court practice has crystallised in ways that were not fully foreseeable when the initial legislative changes were enacted — and the pharmaceuticals sector, given its strategic classification under Russian regulatory policy and its intersection with parallel import liberalisation, has attracted a distinct body of judicial and administrative interpretation that diverges in several respects from the general private wealth structuring framework applicable to Russian-origin assets.
Before 2022, the predominant wealth structuring options for Russian-origin pharmaceutical assets relied on combinations of holding structures in Cyprus, the Netherlands, or other treaty jurisdictions, contractual rights channelled through Russian limited liability companies or joint-stock companies, and royalty or licensing arrangements with foreign IP-holding entities. The courts treated these structures as commercially motivated and applied treaty protections in the ordinary way. The principal risk in that era was transfer pricing scrutiny by the Federal Tax Service; the structural framework itself attracted limited challenge.
The position as of early 2027 is materially different in at least three respects.
First, Russian courts have significantly narrowed the circumstances in which foreign-held intermediate structures retain substantive rights over Russian pharmaceutical assets. In a series of decisions issued across the Moscow and Siberian circuits between 2023 and 2026, courts have applied purposive reasoning to disregard intermediate holding layers where the Russian operating entity is assessed to hold the genuine economic substance — effectively compressing the holding chain for purposes of asset control and distributions. The result is that structures which appeared robust on paper have, in a growing number of cases, been treated as transparent for purposes of regulatory compliance obligations attaching to the pharmaceutical licence holder.
Second, the regulatory framework governing state unitary enterprises in the pharmaceutical sector has undergone a significant transition. Under Russian law, state unitary enterprises — a legacy entity form widely used in the public pharmaceutical manufacturing and distribution sector — are subject to a conversion obligation requiring reorganisation into limited liability companies or joint-stock companies. This transition, which has been the subject of extended implementation timelines, is now substantially advanced. For private wealth planning purposes, the practical effect is that pharmaceutical-sector participants who held interests through or alongside state unitary enterprises face a restructured counterparty landscape: the new LLC and JSC forms are in principle more tractable for private wealth structuring, but the conversion process itself has generated valuation disputes, preferential creditor claims, and challenges to pre-conversion contractual arrangements that remain active in the courts. Advisers who have not reviewed the counterparty-conversion status of their clients' Russian pharmaceutical positions since 2024 should treat this as a priority.
Third, the liberalisation of parallel import rules in the pharmaceutical sector — a policy measure introduced to address supply constraints — has altered the IP licensing dimension of wealth structuring for foreign brand owners with Russian distribution arrangements. Courts have declined, in several instances, to enforce exclusive distribution arrangements in ways that historically protected the economic position of foreign IP holders. This reduces the effective value of licensing-based structuring approaches and shifts the analysis towards direct ownership, operational participation, or exit planning.
The private wealth and asset protection framework for Russian-origin assets post-2022 is analysed in general terms in our earlier briefing Wealth structuring options for Russian-origin assets post-2022 and in the comparative analysis Comparative analysis of wealth structuring options for Russian-origin assets. The pharmaceutical sector diverges from that general framework in ways that make sector-specific review essential rather than optional.
Asset-holders most directly affected fall into three categories.
The first category is foreign families and family offices that hold direct or indirect equity interests in Russian pharmaceutical manufacturers, distributors, or pharmacy chains. This group is affected by the holding-structure compression identified above and by the parallel import changes insofar as their Russian entities held exclusive distribution or licensing rights from foreign brand owners.
The second category is foreign IP owners — including individual inventors, family trusts, and private investment vehicles — who licensed pharmaceutical patents or trademarks to Russian entities under arrangements that included royalty flows as a component of wealth planning. The enforceability of those licensing arrangements, and the continued tax efficiency of the royalty structures, requires re-examination in the current environment. The Federal Tax Service has shown increased appetite for challenging royalty flows to foreign IP-holding structures as lacking commercial substance, and the courts have in several instances upheld those challenges, though the prevailing approach is not uniform across circuits.
The third category is advisers, trustees, and family office managers who hold proxy or representative authority over Russian pharmaceutical assets on behalf of HNWI clients. The procedural position of foreign representatives before Russian courts and regulatory authorities has become more nuanced: in some contexts, direct representation by a foreign trustee has been accepted; in others, the absence of a qualified Russian legal entity in the chain of authority has been treated as a procedural bar.
"The pharmaceutical sector sits at the intersection of Russia's strategic-industry policy and its most active area of parallel import reform — which means that structuring assumptions that held in 2021 need to be pressure-tested against a body of court practice that has developed faster than most advisers have tracked."
— Elizaveta Razina, Senior Lawyer, Practice Lead — IP Enforcement, Vetrov & Partners
Understanding which category your clients fall into determines which wealth structuring options remain viable, which require adaptation, and which have effectively closed. For family offices with multi-sector Russian exposure, the pharmaceutical holding should be treated as a distinct sub-portfolio requiring separate legal analysis under the Private Wealth & Asset Protection framework.
If you advise clients with Russian pharmaceutical-sector assets and need a current assessment of available structuring options — make an enquiry: info@vetrovpartners.com |
The practical response to these developments differs by category, but three actions are common to all holders of Russian pharmaceutical-sector assets.
The first is a holding-structure audit. The compression of intermediate holding layers by Russian courts means that structures designed before 2022 should be reviewed for current legal effectiveness — not as a theoretical exercise but as a matter of assessing what rights the Russian operating entity actually holds, what rights the foreign holding structure can enforce, and how those rights are treated for Russian regulatory and tax purposes. This audit is most efficiently conducted jointly with the Russian counsel responsible for the operating entity's regulatory compliance.
The second is a counterparty-status review for any position that involves a former state unitary enterprise. The conversion to LLC or JSC form may have altered contractual rights, changed the identity of the contracting party, or triggered reorganisation-related claims that affect the asset's value or transferability. These issues are frequently invisible to foreign advisers reviewing the position at arm's length. Our earlier analysis of the conversion process and its implications for creditors and counterparties is available through the Matters section of this site.
The third is a reassessment of IP licensing structures in light of the parallel import framework. For foreign IP owners whose Russian pharmaceutical arrangements were built around exclusive licensing or distribution rights, the current position requires analysis of whether the licensing arrangement retains its commercial rationale and whether the royalty flows remain defensible under Russian tax authority scrutiny. In a number of active matters, we have assisted foreign IP holders in restructuring arrangements that remain viable but require adjustment to reflect the changed enforcement landscape.
The range of viable wealth structuring options for Russian-origin assets post-2022 has narrowed, but it has not closed. The structures that continue to function well share certain characteristics: they are built around genuine Russian economic substance, they are not dependent on the enforceability of pre-2022 exclusive arrangements, and they are supported by current Russian legal advice that reflects actual court practice rather than the pre-2022 baseline. Advisers who have not updated their Russian legal analysis since 2023 or 2024 are, in our assessment, operating with an incomplete picture.
For a full assessment of available wealth structuring options for Russian-origin assets in the pharmaceuticals sector, including the interaction of the parallel import framework with IP licensing structures, we recommend a structured engagement with our Private Wealth & Asset Protection team.
To discuss available structuring options for Russian-origin pharmaceutical assets in confidence — make an enquiry: info@vetrovpartners.com |
Q: What specifically changed in Russian court practice regarding wealth structuring for pharmaceutical-sector assets after 2022?
A: Russian courts have, since 2023, applied purposive reasoning to compress intermediate foreign holding structures where the Russian pharmaceutical operating entity is assessed to hold genuine economic substance. This has reduced the practical effect of offshore holding layers in a number of cases. Separately, the mandatory conversion of state unitary enterprises to LLC or JSC form has altered the counterparty landscape, and parallel import liberalisation has weakened the enforceability of exclusive distribution and licensing arrangements. These three shifts — holding-structure compression, GUP conversion, and parallel import reform — interact specifically in the pharmaceutical sector and have not developed uniformly across all circuits.
Q: Which foreign asset-holders are most directly affected by these developments?
A: Three groups are most directly affected: foreign families and family offices with equity interests in Russian pharmaceutical companies; foreign IP owners who rely on royalty flows from Russian pharmaceutical licensing arrangements as a component of wealth planning; and trustees or family office managers holding representative authority over Russian pharmaceutical positions. Each group faces a distinct set of issues. Equity holders need to assess the current enforceability of their holding-structure rights. IP licensors need to review royalty flow defensibility under current Federal Tax Service scrutiny standards. Representatives need to confirm that their procedural standing before Russian authorities remains valid under current rules.
Q: What should advisers do now if they have not reviewed their clients' Russian pharmaceutical positions since 2022 or 2023?
A: The priority actions are a holding-structure audit to assess which rights remain enforceable at the Russian operating-entity level; a counterparty-status review where the position involves a former state unitary enterprise; and a reassessment of any IP licensing arrangement affected by the parallel import framework. These reviews are best conducted with the involvement of current Russian counsel who can advise on actual court practice, not only on the statutory text. Advisers who have not updated their Russian legal analysis since the 2022–2023 period should treat this as an urgent matter given the pace at which court practice has developed.
This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.
Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.
Make an enquiry